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Preamble
These recommendations provide a data-supported
approach to establishing guidelines. They are based on
the following: (1) a formal review and analysis of the
recently published world literature on the topic (MED-
LINE search up to June 2011); (2) the American College
of Physicians’ Manual for Assessing Health Practices and
Designing Practice Guidelines;
1 (3) guideline policies,
including the AASLD Policy on the Development and
Use of Practice Guidelines and the American Gastroen-
terological Association’s Policy Statement on the Use of
Medical Practice Guidelines;
2 and (4) the experience of
the authorsin regard to hepatitis C.
Intended for use by physicians, these recommenda-
tions suggest preferred approaches to the diagnostic,
therapeutic, and preventive aspects of care. They are
intended to be ﬂexible, in contrast to standards of
care, which are inﬂexible policies to be followed in
every case. Speciﬁc recommendations are based on
relevant published information. To more fully charac-
terize the quality of evidence supporting recommenda-
tions, the Practice Guidelines Committee of the
AASLD requires a Class (reﬂecting beneﬁt versus risk)
and Level (assessing strength or certainty) of Evidence
to be assigned and reported with each recommenda-
tion (Table 1, adapted from the American College of
Cardiology and the American Heart Association
Practice Guidelines).
3,4
Introduction
The standard of care (SOC) therapy for patients
with chronic hepatitis C virus (HCV) infection has
been the use of both peginterferon (PegIFN) and riba-
virin (RBV). These drugs are administered for either
48 weeks (HCV genotypes 1, 4, 5, and 6) or for 24
weeks (HCV genotypes 2 and 3), inducing sustained
virologic response (SVR) rates of 40%-50% in those
with genotype 1 and of 80% or more in those with
genotypes 2 and 3 infections.
5-7 Once achieved, an
SVR is associated with long-term clearance of HCV
infection, which is regarded as a virologic ‘‘cure,’’ as
well as with improved morbidity and mortality.
8-10
Two major advances have occurred since the last
update of treatment guidelines for chronic hepatitis C
(CHC) that have changed the optimal treatment regi-
men of genotype 1 chronic HCV infection: the
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1433development of direct-acting antiviral (DAA) agents
11-17
and the identiﬁcation of several single-nucleotide poly-
morphisms associated with spontaneous and treat-
ment-induced clearance of HCV infection.
18,19
Although PegIFN and RBV remain vital components
of therapy, the emergence of DAAs has led to a sub-
stantial improvement in SVR rates and the option of
abbreviated therapy in many patients with genotype 1
chronic HCV infection. A revision of the prior treat-
ment guidelines is therefore necessary, but is based on
data that are presently limited. Accordingly, there may
be need to reconsider some of the recommendations as
additional data become available. These guidelines
review what treatment for genotype 1 chronic HCV
infection is now regarded as optimal, but they do not
address the issue of prioritization of patient selection for
treatment or of treatment of special patient populations.
Direct-Acting Antiviral Agents
There are multiple steps in the viral lifecycle that
represent potential pharmacologic targets. A number
of compounds encompassing at least ﬁve distinct drug
classes are currently under development for the treat-
ment of CHC. Presently, only inhibitors of the HCV
nonstructural protein 3/4A (NS3/4A) serine protease
have been approved by the Food and Drug Adminis-
tration (FDA).
Protease Inhibitors
The NS3/4A serine protease is required for RNA
replication and virion assembly. Two inhibitors of the
NS3/4A serine protease, boceprevir (BOC) and telap-
revir (TVR), have demonstrated potent inhibition of
HCV genotype 1 replication and markedly improved
SVR rates in treatment-naı ¨ve and treatment-experi-
enced patients.
12,13,16,17 Limited phase 2 testing has
shown that TVR also has activity against HCV geno-
type 2 infection but not against genotype 3.
20 With
regard to BOC, there are limited data indicating that
it too, has activity against genotype 2 but also against
genotype 3 HCV infection.
21 However, at this time,
neither drug should be used to treat patients with
genotype 2 or 3 HCV infections, and when adminis-
tered as monotherapy, each PI rapidly selects for resist-
ance variants, leading to virological failure. Combining
either PI with PegIFN and RBV limits selection of
resistant variants and improves antiviral response.
15
Patients Who Have Never Received Therapy
(Treatment-Naı ¨ve Patients)
Boceprevir. The SPRINT-2 trial evaluated BOC in
two cohorts of treatment-naı ¨ve patients: Caucasian and
black patients.
12 The number of patients in the black
cohort was small in comparison to that of the Cauca-
sian cohort and may have been insufﬁcient to provide
an adequate assessment of true response in this popula-
tion. All patients were ﬁrst treated with PegIFN alfa-
2b and weight-based RBV as lead-in therapy for a
period of 4 weeks, followed by one of three regimens:
(1) BOC, PegIFN, and RBV that was administered for
24 weeks if, at study week 8 (week 4 of triple ther-
apy), the HCV RNA level became undetectable (as
deﬁned in the package insert as <10-15 IU/mL),
referred to as response-guided therapy (RGT); if, how-
ever, HCV RNA remained detectable at any visit from
week 8 up to but not including week 24 (i.e., a slow
virological response), BOC was discontinued and the
patient received SOC treatment for an additional 20
weeks (2) BOC, PegIFN, and RBV administered for a
ﬁxed duration of 44 weeks; and (3) PegIFN alfa-2b
and weight-based RBV alone continued for an addi-
tional 44 weeks, representing SOC therapy.
12 The
BOC dose was 800 mg, given by mouth three times
per day with food. The overall SVR rates were higher
in the BOC arms, (63% and 66% respectively) than
Table 1. Grading System for Recommendations
Classiﬁcation Description
Class 1 Conditions for which there is evidence and/or general agreement that a given diagnostic evaluation procedure or
treatment is beneﬁcial, useful, and effective
Class 2 Conditions for which there is conﬂicting evidence and/or a divergence of opinion about the usefulness/efﬁcacy of a
diagnostic evaluation, procedure, or treatment
Class 2a Weight of evidence/opinion is in favor of usefulness/efﬁcacy
Class 2b Usefulness/efﬁcacy is less well established by evidence/opinion
Class 3 Conditions for which there is evidence and/or general agreement that a diagnostic evaluation,
procedure/treatment is not useful/effective and in some cases may be harmful
Level of Evidence Description
Level A Data derived from multiple randomized clinical trials or meta-analyses
Level B Data derived from a single randomized trial, or nonrandomized studies
Level C Only consensus opinion of experts, case studies, or standard-of-care
1434 GHANY ET AL. HEPATOLOGY, October 2011in the SOC arm (38%), but differed according to race
(Fig. 1). The SVR rates among Caucasian patients
were 67% in the RGT, 69% in the ﬁxed duration, and
41% in the SOC arms, respectively.
12 In black
patients, the SVR rates were 42% in the RGT, 53% in
the ﬁxed duration, and 23% in the SOC arms, respec-
tively (Fig. 1).
12 A total of 54% of Caucasian recipi-
ents of BOC experienced a rapid virological response
(RVR; HCV RNA undetectable, <10-15 IU/mL at
week 8, this interval selected because of the 4 week
lead-in). By contrast, only 20% of black recipients of
BOC experienced an RVR. Regardless of race, among
those patients who became HCV RNA negative at
week 8 ( 57% in both BOC arms and 17% in SOC
arm), the SVR rates were 88% in the RGT arm, 90%
in the ﬁxed duration arm and 85% in the arm treated
by SOC, compared to SVR rates of 36%, 40%, and
30%, respectively, if HCV RNA remained detectable
at week 8 (Fig. 2).
12
In subgroup analysis, SVR rates were higher in BOC-
containing regimens across all the pretreatment variables
that had been identiﬁed in previous studies to inﬂuence
response to SOC therapy, including advanced ﬁbrosis,
race, and high pretreatment HCV viral load. Moreover,
the SVR rate in subgroups was similar in both the RGT
and ﬁxed duration arms and therefore, the AASLD and
the FDA support the use of RGT for treatment-naı ¨ve
patients without cirrhosis. The FDA recommends that
patients with compensated cirrhosis should not receive
RGT, however, this is based on limited data and requires
further study. Of note, if the virological response did
not meet criteria for RGT, i.e., a slow virological
response, the FDA recommends (based on modeling)
triple therapy for 32 weeks preceded by the 4 weeks of
SOC treatment), followed by 12 weeks of PegIFN and
RBV alone; a strategy that differs from the phase 3 trial
design. All therapy should be discontinued if the HCV
RNA level is  100 IU/mL at week 12 or  10 to 15 IU/
mL at week 24.
Telaprevir. Two phase 3 trials evaluated the efﬁcacy
of TVR in combination with PegIFN alfa-2a and RBV
in treatment-naı ¨ve patients with genotype 1 chronic
HCV infection.
16,22 Black patients were included but
not as a separate cohort and were insufﬁcient in num-
ber to provide an adequate assessment of true response
in this population. In the ADVANCE trial, patients
received TVR together with PegIFN and RBV for ei-
ther 8 (T8PR) or 12 (T12PR) weeks followed by
PegIFN and RBV alone in a response-guided para-
digm.
16 The TVR dose was 750 mg given by mouth
every 8 hours with food (in particular, a fatty meal).
Patients in the T8PR and T12PR groups who achieved
an ‘‘extended RVR’’ (eRVR)—which for this drug was
deﬁned as undetectable (<10-15 IU/mL) HCV RNA
levels at weeks 4 and 12—stopped therapy at week 24,
whereas those in whom an eRVR did not occur
received a total of 48 weeks of PegIFN and RBV. All
patients in the control group received PegIFN and
RBV therapy for 48 weeks. The overall SVR rates
Fig. 1. Sustained virological response (SVR) rates, overall and
according to race, in treatment-naı ¨ve patients with genotype 1 chronic
HCV infection: Boceprevir (BOC) plus peginterferon (PegIFN) and riba-
virin (RBV) versus standard of care (SOC). All patients were ﬁrst
treated with PegIFN þ RBV for 4 weeks as lead-in therapy followed by
one of three regiments: (1) BOC/PegIFN/RBV RGT - triple therapy for
24 weeks provided HCV RNA levels were negative weeks 8 thorugh
24 – response guided therapy; those with a detectable HCV RNA level
between weeks 8 and 24 received SOC for an additional 20 weeks;
(2) BOC/PegIFN/RBV ﬁxed duration - triple therapy for a ﬁxed duration
of 44 weeks; and (3) SOC - consisted of PegIFN and weight based
RBV administered for 48 weeks.
12
Fig. 2. Sustained virological response (SVR) rates, overall and
based on a rapid virological response (RVR, undetectable HCV RNA at
week 8 [week 4 of triple therapy]) in treatment-naı ¨ve patients with ge-
notype 1 chronic HCV infection: Boceprevir (BOC) plus peginterferon
(PegIFN) versus standard of care (SOC). All patients were ﬁrst treated
with PegIFN þ RBV for 4 weeks as lead-in therapy followed by one of
three regiments: (1) BOC/PegIFN/RBV RGT - patients who achieved an
RVR (undetable HCV RNA at week 8 [week 4 of triple therapy]) contin-
ued treatment for an additional 24 weeks (RGT - response guided
therapy); if an RVR did not develop, treatment with triple therapy con-
tinued to week 28 followed by SOC treatment for 20 weeks. SOC
treatment consisted of PegIFN and RBV administered for 48 weeks.
12
Note that the combined numbers of RVR-positive and RVR-negative
patients are not equivalent to the total number of patients enrolled,
presumably because of missing HCV RNA values at the week 8 time
point.
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69% and 75%, respectively,
16 compared with a rate of
44% in the control group (Table 2 and Fig. 3). Using
the RGT approach, 58% and 57% of patients in the
T12PR and T8PR groups, respectively, attained an
eRVR, 89% and 83% of whom ultimately achieved an
SVR.
16 Thus, developing an eRVR appears to be the
strongest predictor that an SVR will occur.
SVR rates were higher in TVR-containing regimens
compared to SOC treatment among patients with dis-
ease characteristics found previously to be associated
with a poorer response to SOC treatment. Although
few black patients and other difﬁcult-to-treat patient
populations were included in the TVR phase 3 trials,
an improved SVR rate was observed regardless of race,
ethnicity, or level of hepatic ﬁbrosis. With regard to
race, treatment with a TVR-based regimen signiﬁcantly
improved SVR rates in black patients (T8PR, 58%
and T12PR, 62%) compared to the SVR rates
achieved in those treated with the SOC regimen
(25%) (Fig. 3). Moreover, the SVR rate was >80%
among black patients who achieved an eRVR on a
TVR-based regimen. A total of 62% of patients in the
T12PR group and 53% in the T8PR group with
advanced ﬁbrosis achieved an SVR, the rate improving
to >80% among those with an eRVR. In the T12PR
group, the impact of high versus low viral load
(>800,000 or <800,000 IU/mL) on SVR rates was
minimal; the SVR rate was 74% in patients with a
Table 2. Comparison of Protease Inhibitors in Combination with Peginterferon Alfa (PegIFN) and Ribavirin (RBV) in
Treatment-Naive Subjects
Variable Boceprevir (BOC)
12 Telaprevir (TVR)
16
Study design RCT RCT
4-Week lead-in PegIFN/RBV Yes No
Duration of triple therapy 24 or 44 weeks in combination
with PegIFN/RBV*
12 weeks followed by 12 or
36 weeks PegIFN/RBV†
Response-guided therapy (RGT) Yes Yes
Eligible for response-guided therapy (%) 44 58
SVR (%) BOC44/PR: 66 T8PR: 69
BOC/PR/RGT: 63 T12PR: 75
SOC: 38 SOC: 44
End of treatment response (%) BOC44/PR: 76 T8PR: 81
BOC/PR/RGT: 71 T12PR: 87
SOC: 53 SOC: 63
Relapse (%) BOC44/PR: 9 T8PR: 9
BOC/PR/RGT: 9 T12PR: 9
SOC: 22 SOC: 28
Treatment emergent resistance (%) 16 12
Adverse event more frequent in triple therapy arm compared to SOC Anemia, dysgeusia Rash, anemia, pruritus, nausea, diarrhea
Adverse events leading to treatment discontinuation (%) NA 12
Serious adverse events study drug vs SOC (%) 11 vs 9 9 vs 7
NA, not available; PR, peginterferon plus ribavirin; RCT, randomized, controlled trial; SOC, standard of care; SVR, sustained virological response.
*All patients were ﬁrst treated with PegIFN alfa-2b and weight-based RBV as lead-in therapy for a period of 4 weeks, followed by one of three regimens: (1)
BOC/PR/RGT: BOC, PegIFN, and RBV that was administered for 24 weeks if, at study week 8 (week 4 of triple therapy), the HCV RNA level became undetectable
(as deﬁned in the package insert as <10-15 IU/mL), referred to as response-guided therapy (RGT); if, however, HCV RNA remained detectable at any visit from
week 8 up to but not including week 24 (i.e., a slow virological response), BOC was discontinued and the patient received SOC treatment for an additional2 0
weeks; (2) BOC44/PR: BOC, PegIFN, and RBV administered for a ﬁxed duration of 44 weeks; and (3) SOC: PegIFN alfa-2b and weight-based RBV alone continued
for an additional 44 weeks.
†Telaprevir (TVR) plus peginterferon and ribavirin (PR) treatment for 8 (T8PR) or 12 (T12PR) weeks versus standard of care (SOC). Patients in the T8PR and
T12PR groups who achieved an ‘‘extended RVR’’ (eRVR), which for this drug was deﬁned as undetectable (<10-15 IU/mL) HCV RNA levels at weeks 4 and 12,
stopped therapy at week 24, whereas those in whom an eRVR did not occur received a total of 48 weeks of PegIFN and RBV. All patients in the control group
received PegIFN and RBV therapy for 48 weeks.
Fig. 3. Sustained virological response (SVR) rates, overall and
according to race, in treatment naı ¨ve patients with genotype 1 chronic
HCV infection: Telaprevir (TVR) plus peginterferon and ribavirin (PR)
treatment for 8 (T8PR) or 12 (T12PR) weeks versus standard of care
(SOC). Patients in the triple therapy arms who developed an eRVR
(extended rapid virological response; deﬁned as undetectable HCV
RNA at weeks 4 and 12) stopped treatment at week 24 (response-
guided therapy, RGT); if eRVR did not develop, treatment continued to
48 weeks. SOC treatment consisted of PegIFN and RBV administered
for 48 weeks.
16
1436 GHANY ET AL. HEPATOLOGY, October 2011high viral load and 78% in those with a low viral
load.
The ILLUMINATE trial focused on deﬁning the
utility of RGT in patients with an eRVR. All patients
received an initial 12 weeks of TVR-based triple ther-
apy followed by PegIFN and RBV therapy alone.
22
Those who achieved an eRVR were randomized at
week 20 to receive either an additional 4 or an addi-
tional 28 weeks of PegIFN and RBV whereas those
who failed to achieve an eRVR were not randomized
and received an additional 28 weeks of PegIFN and
RBV. The overall SVR rate for all patients was 72%
(Fig. 4), similar to the 75% rate found in the
ADVANCE trial.
22 Among the 65% of patients who
achieved an eRVR and received either an additional 4
or 28 weeks of PegIFN and RBV, SVR rates were
92% and 88%, respectively (Fig. 4). By contrast, the
SVR rate was only 64% among patients who did not
achieve an eRVR.
22 These data suggest that a
response-guided strategy based on eRVR permits a
shortened duration of therapy without jeopardizing the
SVR response rate and may be appropriate for up to
two-thirds of patients with genotype 1 chronic HCV
infection. The use of RGTmay, however, be unsuitable
for patients with cirrhosis, but at present the data are
insufﬁcient to guide management in this difﬁcult-to-
treat population. Therapy should be discontinued in
all patients if HCV RNA levels are  1,000 IU/mL at
weeks 4 or 12 and/or >10-15 IU/mL at week 24.
Recommendations:
1. The optimal therapy for genotype 1, chronic
HCV infection is the use of boceprevir or telaprevir in
combination with peginterferon alfa and ribavirin
(Class 1,Level A).
2. Boceprevir and telaprevir should not be used
without peginterferon alfa and weight-based riba-
virin (Class 1, Level A).
For Treatment-Naı¨ve Patients:
3. The recommended dose of boceprevir is 800 mg
administered with food three times per day (every 7-
9 hours) together with peginterferon alfa and
weight-based ribavirin for 24-44 weeks preceded by
4 weeks of lead-in treatment with peginterferon alfa
and ribavirin alone (Class 1, Level A).
4. Patients without cirrhosis treated with bocepre-
vir, peginterferon, and ribavirin, preceded by 4
weeks of lead-in peginterferon and ribavirin, whose
HCV RNA level at weeks 8 and 24 is undetectable,
may be considered for a shortened duration of treat-
ment of 28 weeks in total (4 weeks lead-in with
peginterferon and ribavirin followed by 24 weeks of
triple therapy) (Class 2a, Level B).
5. Treatment with all three drugs (boceprevir,
peginterferon alfa, and ribavirin) should be stopped
if the HCV RNA level is >100 IU/mL at treatment
week 12 or detectable at treatment week 24 (Class
2a, Level B).
6. The recommended dose of telaprevir is 750 mg
administered with food (not low-fat) three times per
day (every 7-9 hours) together with peginterferon
alfa and weight-based ribavirin for 12 weeks fol-
lowed by an additional 12-36 weeks of peginterferon
alfa and ribavirin (Class 1, Level A).
7. Patients without cirrhosis treated with telapre-
vir, peginterferon, and ribavirin, whose HCV RNA
level at weeks 4 and 12 is undetectable should be
considered for a shortened duration of therapy of 24
weeks (Class 2a, Level A).
8. Patients with cirrhosis treated with either
boceprevir or telaprevir in combination with pegin-
terferon and ribavirin should receive therapy for a
duration of 48 weeks (Class 2b, Level B).
9. Treatment with all three drugs (telaprevir,
peginterferon alfa, and ribavirin) should be stopped
if the HCV RNA level is >1,000 IU/mL at treat-
ment weeks 4 or 12 and/or detectable at treatment
week 24 (Class 2a, Level B).
Patients Who Have Previously Received
Therapy
Three categories have been deﬁned for persons who
had received previous therapy for CHC but who had
Fig. 4. Sustained virological response (SVR) rates in treatment na-
ı ¨ve patients with genotype 1 chronic HCV infection: Telaprevir (TVR)
plus peginterferon and ribavirin (PR) results overall and among those
who did or did not achieve an eRVR (extended rapid virological
response; undetectable HCV RNA at weeks 4 and 12). Patients who
achieved an eRVR were randomized at week 20 to receive an addi-
tional 4 or an additional 28 weeks of SOC therapy; those who did not
develop an eRVR were not randomized and all received an additional
24 weeks of SOC therapy.
22
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whose HCV RNA level did not decline by at least 2
log IU/mL at treatment week 12; partial responders
are persons whose HCV RNA level dropped by at least
2 log IU/mL at treatment week 12 but in whom
HCV RNA was still detected at treatment week 24;
and relapsers are persons whose HCV RNA became
undetectable during treatment, but then reappeared
after treatment ended. Taking these categories into
account, phase 3 trials have been performed also in
treatment-experienced patients with genotype 1
chronic HCV infection using BOC and TVR in com-
bination with PegIFN and RBV. The BOC trial design
included a 4-week lead-in phase of PegIFN and RBV
and compared response-guided triple therapy (BOC
plus PegIFN and RBV for 32 weeks; patients with a
detectable HCV RNA level at week 8 received SOC
for an additional 12 weeks) and a ﬁxed duration of tri-
ple therapy given for 44 weeks (total 48 weeks of ther-
apy), to SOC therapy.
13 The TVR trial design con-
sisted of three arms: in the ﬁrst arm, patients received
triple therapy for 12 weeks followed by SOC treat-
ment for 36 weeks; in the second arm, patients
received lead-in treatment with SOC for 4 weeks, fol-
lowed by triple therapy for 12 weeks, ending with
SOC treatment for 32 weeks; the third arm consisted
of SOC treatment for 48 weeks.
17 In both trials, an
SVR occurred signiﬁcantly more frequently in those
who received the triple therapy regimens than in those
who received the SOC therapy. In the BOC trial
(RESPOND-2 Trial), the SVR rates were 66% and
59% in the two triple therapy arms compared to 21%
in the control arm, prior relapsers achieving higher SVR
rates (75% and 69%, respectively) than prior partial res-
ponders (52% and 40%, respectively) compared to the
rates attained in the SOC arm (29% and 7%, respec-
tively); null responders were excluded from this trial
(Table 3 and Fig. 5).
13 Similarly, the SVR rates in the
TVR trial (REALIZE Study) were 64% and 66% in the
TVR-containing arms (83% and 88% in relapsers, 59%
and 54% in partial responders, and 29% and 33% in
null responders) and 17% in the control arm (24% in
relapsers, 15% in partial responders and 5% in null res-
ponders) (Fig. 6).
17 Thus, the response to the triple
therapy regimen in both the BOC and TVR trials was
inﬂuenced by the outcome of the previous treatment
with PegIFN and RBV which highlights the importance
of reviewing old treatment records to document previ-
ous treatment response. In the BOC trial, the SVR rate
was higher in those who were relapsers than in those
who were partial responders. In the TVR trial also, the
highest SVR rate occurred in prior relapsers, a lower
Table 3. Comparison of Protease Inhibitors in Combination
with Peginterferon Alfa (PegIFN) and Ribavirin (RBV) in
Treatment-Experienced Patients
Variable Boceprevir (BOC)
13 Telaprevir (TVR)
17
Study design RCT RCT
4-Week lead-in
PegIFN/RBV
Yes Yes/No*
Duration of triple
therapy
32 or 44 weeks in
combination
with PegIFN and RBV
**
12 weeks followed
by 36 weeks
of PegIFN and RBV
***
Response-guided
therapy (RGT)
Yes No
Eligible for RGT (%) 46 NA
Prior response to PegIFN/RBV (%)
Relapser 64 53
Partial responder 36 19
Null responder NA 28
Efﬁcacy, SVR (%)
Relapser BOC/PR48: 75 T12/PR48: 83
BOC/RGT: 69 LI-T12/PR48: 88
PR48: 29 PR48: 24
Partial responder BOC/PR48: 52 T12/PR48: 59
BOC/RGT: 40 LI-T12/PR48: 54
PR48: 7 PR48: 15
Null responder NA T12/PR48: 29
LI-T12/PR48: 33
PR48: 5
Overall relapse (%) 12-15 NA
Relapser NA T12/PR48: 7
LI-T12/PR48: 7
PR48: 65
Partial responder NA T12/PR48: 21
LI-T12/PR48: 25
PR48: 0
Null responder NA T12/PR48: 27
LI-T12/PR48: 25
PR48: 60
Adverse events
Discontinuation (%) 8-12 NA
SAE (%) 10-14 11-15
Adverse event more frequent
in triple therapy arm
Anemia, dysgeusia Rash, anemia, pruritus,
nausea, diarrhea
NA, not available; PR, peginterferon plus ribavirin; RCT, randomized, con-
trolled trial; SAE, serious adverse event; SVR, sustained virological response.
*A lead-in arm was included in the telaprevir retreatment trial but the FDA
approved regimen did not include a lead-in strategy.
†The BOC trial design included a 4-week lead-in phase of PegIFN and RBV
and compared response-guided triple therapy and a ﬁxed duration triple therapy
given for 44 weeks to peginterferon and ribavirin therapy. BOC/RGT response-
guided therapy patients who achieved an eRVR (undetectable HCV RNA at week
8 [week 4 of triple therapy]) received an additional 24 weeks (total 32 weeks
of therapy). If an eRVR was not achieved but HCV RNA became undetectable
at week 12, BOC was stopped at week 32, and patients received an additional
12 weeks of SOC treatment (total 48 weeks of therapy). BOC/PR48: 4-week
lead-in with peginterferon and ribavirin followed by a ﬁxed duration of triple
therapy for 44 weeks; PR48: PegIFN and RBV administered for 48 weeks.
‡Telaprevir (TVR) plus peginterferon and ribavirin (PR) administered with and
without a 4 week SOC treatment lead in versus standard of care (SOC).
T12PR48: TVR administered for 12 weeks followed by 36 weeks of peginter-
feron and ribavirin; LI-T12/PR48: peginterferon and ribavirin for 4 weeks fol-
lowed by TVR plus peginterferon and ribavirin for 12 weeks, followed by
peginterferon and ribavirin for 32 weeks; PR48: peginterferon and ribavirin
administered for 48 weeks.
1438 GHANY ET AL. HEPATOLOGY, October 2011rate in partial responders, and the lowest rate in null
responders (deﬁned as patients who had <2l o g 10
decline in HCV RNA at week 12 of prior treatment)
(Table 3 and Fig. 6).
17
Thus, the decision to re-treat patients should
depend on their prior response to PegIFN and RBV,
as well as on the reasons for why they may have failed,
such as inadequate drug dosing or side effect manage-
ment. Relapsers and partial responder patients can
expect relatively high SVR rates to re-treatment with a
PI-containing triple regimen and should be considered
candidates for re-treatment. The decision to re-treat a
null responder should be individualized, particularly in
patients with cirrhosis, because fewer than one-third of
null responder patients in the TVR trial achieved an
SVR; there are no comparable data for BOC because
null responders were excluded from treatment. In
addition, a majority of null responders developed anti-
viral resistance. The FDA label, however, indicates that
BOC can be used in null responders but, given the
lack of deﬁnitive information from phase 3 data, cau-
tion is advised in the use of BOC in null responders
until further supportive evidence becomes available.
Accordingly, any potential for beneﬁt from treating
nonresponders must be weighed against the risk of de-
velopment of antiviral resistance and of serious side
effects, and the high cost of therapy.
Response-guided therapy, based on achieving an
eRVR, was evaluated for retreatment in the BOC trial.
Shortening the duration of therapy from the standard
48 weeks to 36 weeks in patients who received triple
therapy and who achieved an eRVR (which for this drug
w a sd e ﬁ n e da sH C VR N An e g a t i v ew e e k s8t h r o u g h
20) did not signiﬁcantly lower the SVR rate (59% for
RGT versus 66% for ﬁxed duration treatment).
13 In
patients with cirrhosis, however, the SVR rate was statis-
tically lower in those who received RGT therapy than in
those who were treated for the full 48-week duration
(35% versus 77%, respectively).
13 The emergence of
BOC resistant variants was more common among
patients who responded poorly to interferon treatment
(<1 log decline in HCV RNA level) during the lead-in
p h a s ea n dw h ow e r et r e a t e dw i t hR G Tc o m p a r e dt o
those with >1 log decline in HCV RNA level and
treated for 48 weeks (32% and 8%, respectively).
13
There are no comparable data for RGT using TVR.
Nonetheless, SVR rates are at least as high in relapsers
as in treatment-naı ¨ve patients, and TVR exposure is 12
weeks with both RGT and 48-week treatment options.
Accordingly, although there are no direct data to support
the recommendation that relapsers could be treated with
TVR using an RGT approach, the FDA does endorse
such a recommendation, as is the case for BOC.
Utility of Lead-In
There is uncertainty about the beneﬁt of a lead-in
phase. Theoretically, a PegIFN and RBV lead-in phase
may serve to improve treatment efﬁcacy by lowering
HCV RNA levels which would allow for steady-state
PegIFN and RBV levels at the time the PI is dosed,
thereby reducing the risk of viral breakthrough
or resistance. In addition, a lead-in strategy does allow
for determination of interferon responsiveness and
on-treatment assessment of SVR in patients receiving
either BOC or TVR. Patients whose interferon response
is suboptimal, deﬁned as a reduction of the HCV RNA
level of less than 1 log during the 4-week lead-in, have
Fig. 5. Sustained virological response (SVR) rates, overall and
among relapsers and partial responders, in treatment experienced
patients with genotype 1 chronic HCV infection: Boceprevir (BOC) plus
peginterferon and ribavirin (PR) versus standard of care (SOC). All
patients were ﬁrst treated with PegIFN and RBV for 4 weeks as lead-in
therapy followed by one of 3 regimens: (1) BOC/PR48 triple therapy
for 44 weeks. (2) BOC RGT triple therapy for 32 weeks if an eRVR was
achieved (undetecatble HCV RNA at week 8 and 12). If an eRVR was
not achieved, but HCV RNA became undetectable at week 12, BOC
was stopped at week 32 and patients received an additional 12
weeks of SOC treatment (total 48 weeks of therapy). (3) SOC treat-
ment consisted of PegIFN and RBV administered for 48 weeks.
13
Fig. 6. Sustained virological response (SVR) rates, overall and among
relapsers, partial responders, and null responders, in treatment-experi-
enced patients with genotype 1 chronic HCV infection. T12PR48: Telap-
revir (TVR) plus peginterferon and ribavirin (PR) administered for
12 weeks followed by 36 PR for 12 weeks followed by PR for 32 weeks;
SOC consisted of PegIFN and RBV administered for 48 weeks.
17
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response during lead-in treatment.
12 Nevertheless, the
addition of BOC to poor responders during lead-in still
leads to signiﬁcantly improved SVR rates (28% to 38%
compared with 4% if a PI is not added) and thus a poor
response during the lead-in phase should not be used to
deny patients access to PI therapy.
A direct comparison of the lead-in and non-lead-in
groups in the BOC phase 2 study, however, did not
show a signiﬁcant difference in SVR rates for either
the 28 week regimen, 56% and 54%, or the 48 week
regimen, 75% and 67%, treated with and without
lead-in, respectively.
11 Combining data across all treat-
ment groups in the phase 2 trial demonstrated a trend
for a higher rate of virological breakthrough in the
BOC-treated patients without a lead-in, 9%, than in
those who received lead-in treatment, 4%, (P ¼ 0.06).
However, because all the phase 3 data were based on
the lead-in strategy, until there is evidence to the con-
trary, BOC should be used with a 4-week lead-in. A
lead-in strategy was not evaluated in the phase 3 TVR
treatment-naı ¨ve trial, and therefore no recommenda-
tion can be made for this drug.
Recommendations:
For treatment-experienced patients:
10. Re-treatment with boceprevir or telaprevir,
together with peginterferon alfa and weight-based
ribavirin, can be recommended for patients who had
virological relapse or were partial responders after a
prior course of treatment with standard interferon
alfa or peginterferon alfa and/or ribavirin (Class 1,
Level A).
11. Re-treatment with telaprevir, together with
peginterferon alfa and weight-based ribavirin, may
be considered for prior null responders to a course
of standard interferon alfa or peginterferon alfa
and/or weight-based ribavirin (Class 2b, Level B.)
12. Response-guided therapy of treatment-experi-
enced patients using either a boceprevir- or telapre-
vir-based regimen can be considered for relapsers
(Class 2a, Level B for boceprevir; Class 2b, Level C
for telaprevir), may be considered for partial respond-
ers (Class 2b, Level B for boceprevir; Class 3, Level C
for telaprevir), but cannot be recommended for null
responders (Class 3, Level C).
13. Patients re-treated with boceprevir plus
peginterferon alfa and ribavirin who continue to
have detectable HCV RNA > 100 IU at week 12
should be withdrawn from all therapy because of the
high likelihood of developing antiviral resistance
(Class 1, Level B).
14. Patients re-treated with telaprevir plus pegin-
terferon alfa and ribavirin who continue to have
detectable HCV RNA > 1,000 IU at weeks 4 or 12
should be withdrawn from all therapy because of the
high likelihood of developing antiviral resistance
(Class 1, Level B).
Adverse Events
Adverse events occurred more frequently in patients
treated with PIs than in those treated with PegIFN
and RBV therapy alone. In the BOC trials, anemia
and dysgeusia were the most common adverse events,
whereas in the TVR trials, rash, anemia, pruritus, nau-
sea, and diarrhea developed more commonly among
those who received TVR than who received SOC ther-
apy.
12,16 In the phase 3 TVR trials, a rash of any se-
verity was noted in 56% of patients who received a
TVR-based regimen compared to 32% of those who
received a PegIFN and RBV regimen.
16 The rash was
typically eczematous and maculopapular in character,
consistent with a drug-induced eruption. In most
patients, the rash was mild to moderate in severity but
was severe (involving >50% of the body surface area)
in 4% of cases. The development of rash necessitated
discontinuation of TVR in 6% and of the entire
regimen in 1% of the cases. The Stevens Johnson Syn-
drome or Drug-Related Eruption with Systemic Symp-
toms (DRESS) occurred in <1% of subjects but at a
higher frequency than generally observed for other
drugs. The response of the rash to local or systemic
treatment with corticosteroids and oral antihistamines
is uncertain. Pruritus, commonly but not always asso-
ciated with rash, was noted in  50% of patients who
received TVR therapy.
16
Anemia developed among recipients of both PIs. He-
moglobin decreases below 10 g/dL (grade 2 toxicity)
occurred in 49% of patients who received a BOC regi-
men compared to 29% of those who received the SOC
regimen, whereas 9% had a hemoglobin decline of <8.5
g/dL (grade 3 toxicity).
12 Among patients treated with
T12PR, hemoglobin levels of <10 g/dL were observed
in 36% of patients compared to in 14% of patients who
received SOC, and 9% had hemoglobin decreases to
<8.5 g/dL.
16 Because hematopoietic growth factors
were not permitted during the TVR trials, there was a
5%-6% higher rate of treatment discontinuation among
those who developed anemia than among those who did
not. However, neither anemia nor RBV dose reduction
adversely affected the SVR rate. Of note is that in the
BOC trial, SVR rates in patients managed by RBV dose
reduction alone were comparable to those in patients
1440 GHANY ET AL. HEPATOLOGY, October 2011managed with erythropoietin therapy.
23 Similarly, in the
TVR trials, dose reduction of RBV had no effect on
SVR rates, and therefore dose reduction should be the
initial response to management of anemia.
24 Because
the duration of BOC therapy (24 to 44 weeks) is longer
than the duration of TVR therapy (12 weeks), the fre-
quency of anemia is likely to be greater in BOC-con-
taining regimens, leading to more RBV dose reductions
and consideration of erythropoietin use. However, the
potential beneﬁts of erythropoietin must be weighed
against its potential side effects, the fact that its use in
HCV therapy is not approved by the FDA, and its con-
siderable cost. If a PI treatment–limiting adverse event
occurs, PegIFN and RBV can be continued provided
that an on-treatment response had occurred. There are
no data to help guide substitution of one for the other
HCV PI. If a patient has a serious adverse reaction
related to PegIFN and/or RBV, the PegIFN and/or
RBV dose should be reduced or discontinued. If either
PegIFN and/or RBV are discontinued, the HCV PI
should be stopped. Additional information on manage-
ment of other adverse events can be found in the pack-
age insert.
Drug–Drug Interactions
Because patients with CHC frequently receive medi-
cations in addition to those used to treat HCV infec-
tion, and because the PIs can inhibit hepatic drug-
metabolizing enzymes such as cytochrome P450 2C
(CYP2C), CYP3A4, or CYP1A, both BOC and TVR
were studied for potential interactions with a number
of drugs likely to be coadministered. These included
statins, immune suppressants, drugs used to treat HIV
coinfection, opportunistic infections, mood disorders,
and drug addiction support medications. Both BOC
and TVR, were noted to cause interactions with
several of the drugs examined, either increasing or
decreasing pharmacokinetic parameters. It is particu-
larly important, therefore, that the medical provider
review this information as listed in the package
insert for each of the drugs before starting
treatment for CHC. This information can be
obtained at the FDA Web site: www.accessdata.fda.
gov/scripts/cder/drugsatfda/index.cfm. Other helpful
sites are: http//:222.drug-interactions.com and www.
hep-druginteractions.org
Viral Resistance and Monitoring
Emergence of antiviral-resistant variants during
PI-based therapy has been observed during all trials
and is associated with virological failure and relapse
(Tables 2 and 3). Mutations that confer either high or
low level resistance to BOC and TVR cluster around
the catalytic site of the NS3/4A serine protease. Simi-
lar variants were detected in both BOC and TVR-
treated subjects, suggesting that some degree of cross-
resistance exists between the two PIs. In both phase 3
studies, sequence analysis of the NS3/4A region was
performed in all subjects at baseline and for all sub-
jects who failed to achieve an SVR. Antiviral resistant
variants were detected in a small proportion of patients
at baseline, 7% in the BOC studies and 5% in the
TVR trials, but did not appear to impact response to
either PI.
25,26 Therefore, there is currently no clinical
indication for baseline resistance testing.
Among treatment-naı ¨ve patients receiving a BOC
regimen, antiviral resistant variants developing during
treatment were observed overall in 16% of patients
(Table 2).
12 During treatment, TVR-associated antivi-
ral variants occurred in 12% of treatment-naı ¨ve
patients and 22% of treatment-experienced patients
(Tables 2 and 3).
16,17 A majority (80%-90%) of
patients who experienced virological breakthrough or
incomplete virological suppression on therapy, or viro-
logical relapse after discontinuation of PI therapy, were
found to have antiviral resistant variants. In the BOC
studies, poor response to interferon (<1 log decline in
HCV RNA during the lead-in phase) was associated
with a higher rate of development of resistance.
12
Among TVR-treated patients, population sequencing
has suggested that high-level resistance develops more
commonly when virological failure occurs during the
initial 12 weeks of treatment, whereas low-level resist-
ance variants are more likely when virological failure
occurs later, during treatment with PegIFN and RBV
alone. These observations highlight the importance of
response to interferon for the prevention of emergence
of antiviral resistance.
The clinical signiﬁcance of antiviral resistant variants
that emerge during PI therapy is uncertain. In longitu-
dinal follow-up of patients enrolled in phase 2 trials,
BOC-resistant variants were detected in 43% of sub-
jects after 2 years of follow-up. Similarly, among
patients with documented TVR-resistant variants who
were enrolled in the TVR phase 3 trials, 40% still had
detectable resistant variants after a median follow-up
period of 45 weeks.
27 In general, the decline or loss of
variants appears to be related to their level of ﬁtness.
Further data are needed to determine whether selec-
tion of these variants during and after PI therapy
affects subsequent treatment choices. In phase 3 stud-
ies, the emergence of resistant variants and virological
breakthrough was more common in patients infected
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genetic barrier required for selection of resistant var-
iants in HCV subtype 1b compared to 1a.
28 Thus,
HCV subtyping may play a role in helping to select
future treatment regimens and predict the develop-
ment of resistance. Finally, minimizing development of
compensatory mutations would involve early discon-
tinuation of PI therapy when antiviral therapy is
unlikely to succeed. Although viral stop rules varied
widely in the phase 2 and 3 trials, week 4 and 12 time
points on triple therapy are still key decision
points for stopping therapy based on HCV RNA lev-
els. Current data suggest that for patients receiving
BOC, therapy should be stopped at week 12 if the
viral level is >100 IU/mL or >10-15 IU/mL at
treatment week 24 and, for TVR, therapy should be
stopped at either week 4 or 12 if the viral level
is >1,000 IU/mL or if week 24 HCV RNA is
detectable.
Recommendations:
15. Patients who develop anemia on protease in-
hibitor-based therapy for chronic hepatitis C should
be managed by reducing the ribavirin dose (Class
2a, Level A).
16. Patients on protease inhibitor-based therapy
should undergo close monitoring of HCV RNA levels
and the protease inhibitors should be discontinued
if virological breakthrough (>1 log increase in se-
rum HCV RNA above nadir) is observed (Class 1,
Level A).
17. Patients who fail to have a virological
response, who experience virological breakthrough,
or who relapse on one protease inhibitor should not
be re-treated with the other protease inhibitor (Class
2a, Level C).
Role of IL28B Testing in Decision to Treat
and Selection of Therapeutic Regimen
The likelihood of achieving an SVR with PegIFN and
RBV and of spontaneous resolution of HCV infection
differ depending on the nucleotide sequence near the
gene for IL28B or lambda interferon 3 on chromosome
19.
18,19 One single-nucleotide polymorphism that is
highly predictive is detection of the C or Tallele at posi-
tion rs12979860.
18 The CC genotype is found more
than twice as frequently in persons who have spontane-
ously cleared HCV infection than in those who had pro-
gressed to CHC. Among persons with genotype 1
chronic HCV infection who are treated with PegIFNand
RBV, SVR is achieved in 69%, 33%, and 27% of Cauca-
sians who have the CC, CT, and TT genotypes, respec-
tively; among black patients, SVR rates were 48%, 15%,
and 13% for CC, CT, and TT genotypes, respectively.
29
The predictive value of IL28B genotype testing for SVR
is superior to that of the pretreatment HCV RNA
level, ﬁbrosis stage, age, and sex, and is higher for HCV
genotype 1 virus than for genotypes 2 and 3 viruses.
29,30
There are other polymorphisms near the gene for IL28B
that also predict SVR, including detection of the G or
T allele at position rs8099917, where T is the favorable
genotype, and essentially provides the same information
in Caucasians as C at rs12979860.
31,32
In one study, as well as in preliminary analyses of
the phase 3 registration data, IL28B genotype
remained predictive of SVR even in persons taking
BOC or TVR.
33 In Caucasian patients randomized in
the SPRINT 2 trial to take BOC for 48 weeks, SVR
was achieved by 80%, 71%, and 59% of patients with
CC, CT, and TT genotypes, respectively.
34 In Cauca-
sian patients randomized in the ADVANCE trial to
take TVR for 12 weeks, SVR was achieved by 90%,
71%, and 73% of patients with CC, CT, and TT ge-
notypes, respectively.
35 IL28B genotype also predicts
the likelihood of qualifying for RGT. In treatment-na-
ı ¨ve Caucasian patients randomized in SPRINT 2 to
BOC, the week 8 HCV RNA threshold was achieved
in 89% and 52% of patients with CC and CT/TT ge-
notypes, respectively.
34 In treatment-naı ¨ve Caucasian
patients randomized in the ADVANCE study to TVR,
eRVR was achieved in 78%, 57%, and 45% of patients
with CC, CT, and TT genotypes, respectively.
35
Although the IL28B genotype provides information
regarding the probability of SVR and abbreviated ther-
apy that may be important to provider and patient, there
are insufﬁcient data to support withholding PIs from
persons with the favorable CC genotype because of the
potential to abbreviate therapy and the trend for higher
SVR rates observed in the TVR study. In addition, the
negative predictive value of the Tallele with PI-inclusive
therapy is not sufﬁciently high to restrict therapy for all
patients, because SVR was achieved by more than half of
Caucasians with the TT genotype.
34,35
In summary, these data indicate that IL28B geno-
type is a signiﬁcant pretreatment predictor of response
to therapy. Consideration should be given to ordering
the test when it is likely to inﬂuence either the physi-
cian’s or patient’s decision to initiate therapy. There are
insufﬁcient data to determine whether IL28B testing
can be used to recommend selection of SOC over a
PI-based regimen with a favorable genotype (CC) and
in deciding upon the duration of therapy with either
regimen.
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18. IL28B genotype is a robust pretreatment pre-
dictor of SVR to peginterferon alfa and ribavirin as
well as to protease inhibitor triple therapy in
patients with genotype 1 chronic hepatitis C virus
infection. Testing may be considered when the
patient or provider wish additional information on
the probability of treatment response or on the prob-
able treatment duration needed (Class 2a, Level B).
Special Populations
There is a paucity of information for many of the
subgroups with the greatest unmet need for treatment
(e.g., patients coinfected with HIV and HCV, those
with decompensated cirrhosis, and those after liver
transplantation). Data from phase 1 and 2 trials have
provided interim information that may guide related
treatment issues. BOC and TVR undergo extensive
hepatic metabolism, BOC primarily by way of the
aldoketoreductase (AKR) system but also by the cyto-
chrome P450 enzyme system, whereas TVR is metabo-
lized only by the cytochrome P450 enzyme system,
and the main route of elimination is via the feces with
minimal urinary excretion. Thus, no dose adjustment
of BOC or TVR is required in patients with renal
insufﬁciency. No clinically signiﬁcant differences in
pharmacokinetic parameters were observed with varying
degrees of chronic liver impairment in patients treated
with BOC and therefore, no dosage adjustment of this
drug is required in patients with cirrhosis and liver
impairment. Although TVR may be used to treat
patients with mild hepatic impairment (Child-Turcotte--
Pugh class A, score 5 or 6), it should not be used in
HCV-infected patients with moderate to severe hepatic
impairment, because no pharmacokinetic or safety data
are available regarding its use in such patients. As noted
above, BOC and TVR are both inhibitors of CYP3A4,
and concomitant administration of medications known
to be CYP3A4 substrates should be done with caution
and under close clinical monitoring. Pharmacokinetic
interactions have particular implications in HIV-coin-
fected and transplant populations, where drug–drug
interactions will complicate treatment paradigms, so
that any use of BOC or TVR in transplant or HIV-
coinfected populations of patients with HCV should be
done with caution and under close clinical monitoring.
TVR and BOC are not recommended for use in chil-
dren and adolescents younger than 18 years of age,
because the safety and efﬁcacy has not been established
in this population. Thus, whereas BOC and TVR have
great promise for improved SVR in special populations,
many complex treatment issues remain to be evaluated
in further phase 2 and 3 testing.
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